ARRAVITE NMN Nicotinamide Mononucleotide Advanced Formulation
Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Public Assessment Report
(PAR)
11-01-2021
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
nicotinamide mononucleotide, Quantity: 150 mg
Available from:
ARRA Pharmaceutical Pty Ltd
Pharmaceutical form:
Tablet, film coated
Composition:
Excipient Ingredients: microcrystalline cellulose; calcium hydrogen phosphate dihydrate; croscarmellose sodium; povidone; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 400; titanium dioxide; Carnauba Wax
Administration route:
Oral
Product summary:
Visual Identification: round shaped white film coated tablet; Container Type: Jar/Can
Authorization status:
Listed (Export Only)
Authorization date:
2020-12-23
